Immunogenicity for Biotherapeutics Session Spotlight: Evaluating Potential Impact of Pharmacodynamic Markers on Immunogenicity Assessment

Leading up to Immunogenicity for Biotherapeutics this April 17-19, 2012 in Washington, DC, we'll be highlighting some of the key sessions at this year's conference.  Today, we're looking at "Evaluating Potential Impact of Pharmacodynamic Markers on Immunogenicity Assessment".

Perhaps the biggest challenge in all of immunology / immunogenicity analysis is the ability to predict an immune response. This session will delve into the status of pharmacodynamic biomarkers to predict immune response and should be of the greatest interest to our audience. It will cover many of the same topics as our extremely popular and highly-listened podcast from Martin Lechmann of Merck-Serono, so people who were interested in that and want more content / takeaway steps should definitely make sure to go to this one!  For more information on Immunogenicity for Biotherapeutics taking place April 17-19, 2012, in Baltimore, MD, download the brochure here.

Featured Session: Evaluating Potential Impact of Pharmacodynamic Markers on Immunogenicity Assessment
Featured Speaker: Joleen White, PhD, Principal Scientist, Biogen Idec
About the session: Pharmacodynamic activity in itself can serve as a biomarker that demonstrates drug functionality, helping to determine safe dosages and making the development of a NAb assay far less essential. But what happens if a biomarker-predicted immune response does not accurately reflect PK/PD? In such contradictory cases, can any useful results be salvaged?

Share this article with your social network, just click below to share now!

Share |